position: EnglishChannel  > Cooperation> Hubei to Support R&D of Innovative Medicines

Hubei to Support R&D of Innovative Medicines

Source: Science and Technology Daily | 2022-05-26 10:05:00 | Author: Li LinXu

By?LI?Linxu

A specialized fund of 10 billion RMB for the life and health industry has been set up to support pharmaceutical companies to be listed at home or abroad, according to a series of measures recently unveiled by East Lake Science City in Wuhan, Hubei province.

Focusing on cultivating major new drug discoveries, improving innovation capabilities, promoting investment, and optimizing industrial ecology, a total of about 20 measures have been introduced to support the industrial development of new medicines.


Wuhan East Lake High-tech Development Zone

Of note is that to support new drug innovation and development, a partner model has been created.

Under this model, the funding support will move forward and the risk of developing new drugs will be shared. For the clinical research of a Class I new drug, the funding support can amount to a maximum of 20 million RMB annually and the accumulative amount of funding support can reach a maximum of 100 million RMB.

In addition, a maximum of 100 million RMB will be allocated to attract top scientists and high-end talent through a talent exchange program.

By the end of 2030, the industrial output value of related pharmaceutical companies is expected to exceed 100 billion RMB, 30 top academicians and experts in the field?will be?introduced,?and 20 listed companies to?be fostered, according to East Lake Science City.

Editor:李林旭

Top News

  • ?Emerging technologies like AI, big data and the Internet of Things are rapidly reshaping the world in this era of digital intelligence. However, they are also bringing challenges to human rights, which makes joint efforts essential. Science and Technology Daily spoke with international experts on these issues against the backdrop of the 2025 China-Europe Seminar on Human Rights hosted by the China Society for Human Rights Studies and Cátedra China Foundation in Madrid, Spain, on June 25 on the theme "Human Rights in the Era of Digital Intelligence."

First Human Clinical Trial of Invasive BCI in China

A major breakthrough in neurotechnology has been achieved with the successful completion of China's first-in-human clinical trial of an invasive brain-computer interface (BCI) system. With that China becomes the second country in the world to reach the clinical stage in this field.

GTCOM Establishes a Strategic Partnership with ITBM to Co-Build Malaysia’s National AI Translation Platform

On June 18, 2025, during the 31st Beijing International Book Fair (BIBF), Global Tone Communication Technology Co., Ltd. (GTCOM) and Malaysian Institute of Translation & Books (ITBM) held a strategic cooperation signing ceremony at China National Convention Center (CNCC), officially launching the development of Malaysia’s National AI Translation Platform.

抱歉,您使用的浏览器版本过低或开启了浏览器兼容模式,这会影响您正常浏览本网页

您可以进行以下操作:

1.将浏览器切换回极速模式

2.点击下面图标升级或更换您的浏览器

3.暂不升级,继续浏览

继续浏览